Biomerieux SA (BIOX.PA) Key Developments | Reuters.com
Edition:
United States

Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

122.25EUR
1 Jul 2016
Change (% chg)

€0.10 (+0.08%)
Prev Close
€122.15
Open
€122.30
Day's High
€123.00
Day's Low
€119.25
Volume
50,339
Avg. Vol
49,774
52-wk High
€123.00
52-wk Low
€93.10

Latest Key Developments (Source: Significant Developments)

Biomerieux and Lyon Civil Hospitals expand their partnership
Wednesday, 1 Jun 2016 01:36am EDT 

Biomerieux SA :Said on Tuesday Biomerieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1.  Full Article

Biomerieux acquires Hyglos
Wednesday, 1 Jun 2016 01:00am EDT 

Biomerieux SA : Biomérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products . Total consideration paid by Biomerieux to acquire 100 pct of Hyglos shares will amount to 24 million euros ($26.69 million) . Total consideration paid by Biomerieux to acquire 100 pct of Hyglos phased over next 3 years . Transaction was closed on May 31, 2016 .Hyglos will be consolidated in group`s financial statements from June 1st, 2016.  Full Article

Biomerieux : Filmarray Torch is FDA cleared
Friday, 8 Apr 2016 01:00am EDT 

Biomerieux SA:Filmarray Torch is now FDA cleared with all 4 existing Filmarray panels and the system gets CE marked.  Full Article

Biomerieux and Copan announce the first commercial success of their collaboration
Tuesday, 22 Mar 2016 02:00am EDT 

Biomerieux SA:Biomerieux and Copan announce the first commercial success of their collaboration for the automation and efficiency of microbiology laboratories.  Full Article

Biomerieux proposes FY 2015 dividend of 1.00 euros/share, comments on FY 2016 guidance
Wednesday, 2 Mar 2016 01:00am EST 

Biomerieux SA:Sees 2016 organic growth in sales of between 6.0 pct and 8.0 pct.Expects 2016 contributive operating income before non-recurring items of between 265-290 million euros.Will recommend that shareholders at annual meeting on May 26 approve an FY 2015 dividend of 1.00 euro per share.  Full Article

Biomerieux says BioFire Receives FDA Clearance for FilmArray Torch
Thursday, 25 Feb 2016 01:15am EST 

Biomerieux SA:Biofire receives FDA clearance for Filmarray torch with Filmarray respiratory panel and submits special 510(K) applications for use with additional Filmarray panels.  Full Article

Biomerieux : Biofire’s Filmarray gets CE marked
Tuesday, 26 Jan 2016 01:00am EST 

Biomerieux SA:Biofire's Filmarray meningitis/encephalitis panel gets CE marked.  Full Article

Biomerieux gives FY 2016 growth guidance
Thursday, 21 Jan 2016 01:00am EST 

Biomerieux SA:Set a 2016 organic growth target of between 6.0 pct and 8.0 pct, on a like-for-like basis.  Full Article

Biomerieux affiliate submitted FilmArray Torch to the FDA
Tuesday, 12 Jan 2016 01:00am EST 

Biomerieux SA:BioFire Diagnostics, LLC, has submitted the FilmArray Torch to the U.S. Food and Drug Administration (FDA) for special 510(k) clearance for use with the FilmArray Respiratory Pane.Biofire announced its intention to seek 510(k) clearance of FilmArray Torch for use with all existing FDA-cleared FilmArray panels in coming weeks.  Full Article

Biomerieux ‍acquires Applied Maths​
Tuesday, 5 Jan 2016 01:00am EST 

Biomerieux SA:Acquires Applied Maths, a company that develops software solutions for the biosciences, in particular for databasing, analysis and interpretation of complex biological data.‍Financial details of transaction have not been disclosed.  Full Article

BRIEF-Biomerieux gets FDA clearance for VIDAS B.R.A.H.M.S PCT test

* Biomerieux receives FDA clearance for expanded use of VIDAS B.R.A.H.M.S PCT test for managing sepsis patients with elevated risk of mortality Source text for Eikon: Further company coverage: (Gdynia Newsroom)